


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

POLL RESULTS OF THE SPECIAL GENERAL MEETINGS HELD ON 30 JULY 2021

POLL RESULTS OF THE SPECIAL GENERAL MEETING IN RELATION TO THE SECOND AMENDMENT

The Board is pleased to announce that the resolution as set out in the Notice was duly passed by the Shareholders by way of poll at the SGM held on 30 July 2021.

References are made to (1) the circular (the “**Circular**”) of Innovative Pharmaceutical Biotech Limited (the “**Company**”) dated 14 July 2021 in relation to the Second Amendment; and (2) the notice of the special general meeting dated 14 July 2021 in relation to the Second Amendment (the “**Notice**”). Unless the context otherwise requires, terms defined in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE SPECIAL GENERAL MEETING IN RELATION TO THE SECOND AMENDMENT

The Board is pleased to announce that at the special general meeting held on 30 July 2021 in relation to the Second Amendment (the “**SGM**”), the proposed ordinary resolution as set out in the Notice (“**Resolution**”) was duly passed by the Shareholders by way of poll pursuant to Rule 13.39(4) of the Listing Rules.

Tricor Tengis Limited, the Company’s branch share registrar, acted as the scrutineer for the purpose of the counting of votes at the SGM. The poll results of the resolution at the SGM are as follows:

ORDINARY RESOLUTION		For		Against	
		Number of Shares	%	Number of Shares	%
1.	To approve, among others, (a) the Second Amendment Deed and all the transactions contemplated thereunder; (b) the allotment and issue of the Conversion Shares upon exercise of the conversion rights attached to the Convertible Bonds under the Specific Mandate; and (c) any Director is authorized to do all such things and acts and execute all such documents, with full details as indicated in the notice of the Meeting.	505,782,580	99.99	104	0.01

As at the date of the SGM, a total of 1,464,193,024 Shares were in issue. As at the date of this announcement, Dr. Mao Yumin, being a substantial shareholder of the Company, holds 363,200,000 Shares directly and 7,770,810 Shares indirectly through China United Gene Investment Holdings Limited (“**China United Gene**”). Dr. Mao Yumin is also a director of certain subsidiaries of the Bondholder and holds approximately 7.94% of the issues shares of the Bondholder. In light of the above, Dr. Mao is materially interested in the Second Amendment. Hence, Dr. Mao Yumin and China United Gene were required to abstain and they did abstain from voting on the Resolution at the SGM. Save as disclosed above, no Shareholders were required to abstain from voting on the resolution proposed at the SGM.

By Order of the Board
Innovative Pharmaceutical Biotech Limited
Gao Yuan Xing
Executive Director

Hong Kong, 30 July 2021

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director) and Mr. Chen Jinzhong (independent non-executive Director).